Feedback / Questions
nilotinib amorphous (XS003) - Xspray Pharma
https://xspraypharma.com/modular_finance_pressmeddelande/xspray-pharma-fda-accepts-new-drug-application-for-xs003-nilotinib-for-the-treatment-of-cml-pdufa-date-set-for-june-18-2026/
Oct 21, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next